Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Rallies By 100% on Positive Clinical Trial Results

923

Dallas, Texas 07/28/2015 (Financialstrend) – Nymox Pharmaceutical Corporation (NASDAQ:NYMX) was a big mover on Monday trading session with the stock rallying by more than 100%. The rally was down to the company announcing that its US long-term extension prospective, double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate had met the primary endpoint with better results than placebo.

 Positive Clinical Trials

 The stock was already up by more than 200% as of last week begging the question as to whether Nymox Pharmaceutical Corporation (NASDAQ:NYMX) can be able to sustain the rally. Clinical trials of Fexapotide showed excellent safety profile with no drug-related toxicity or any molecular side effects.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has already announced plans to meet with authorities with a view to seeking regulatory approval for the use of the drug in various jurisdictions. The drug according to the trials successfully reduced the need for surgery for patients under trial in Phase 3 significantly reducing the need for BPH surgery within 24 months of fexapotide

 The company maintains the new treatment is way superior to other treatments already in use, as it has minimal or no sexual hormonal or debilitating side effects. Phase 2 test results also showed reduced prostate cancer risk with the use of Fexapotide while also resulting in less progression compared to other controls.

 Capital Raising

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) also engages in the research and development of new products that target the needs of the aging population. The company offers NicAlert and TobacAlert tests that detect the use of tobacco products by analyzing saliva and urine. AlzheimAlert is a proprietary urine assay that aids physicians in the diagnosis of Alzheimer disease.

Separately Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recently completed financing for a total of $850,000 after selling a total of 400,000 shares for $1.25 a share to a private European investor. The company also sold an additional 217, 122 shares at a price of $1.66 a share.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.